The impact of immunopeptidomics: From basic research to clinical implementation.

Détails

Ressource 1Télécharger: 1-s2.0-S1044532323000180-main.pdf (1473.08 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_6B56B0492D5F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
The impact of immunopeptidomics: From basic research to clinical implementation.
Périodique
Seminars in immunology
Auteur⸱e⸱s
Shapiro I.E., Bassani-Sternberg M.
ISSN
1096-3618 (Electronic)
ISSN-L
1044-5323
Statut éditorial
Publié
Date de publication
03/2023
Peer-reviewed
Oui
Volume
66
Pages
101727
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The immunopeptidome is the set of peptides presented by the major histocompatibility complex (MHC) molecules, in humans also known as the human leukocyte antigen (HLA), on the surface of cells that mediate T-cell immunosurveillance. The immunopeptidome is a sampling of the cellular proteome and hence it contains information about the health state of cells. The peptide repertoire is influenced by intra- and extra-cellular perturbations - such as in the case of drug exposure, infection, or oncogenic transformation. Immunopeptidomics is the bioanalytical method by which the presented peptides are extracted from biological samples and analyzed by high-performance liquid chromatography coupled to tandem mass spectrometry (MS), resulting in a deep qualitative and quantitative snapshot of the immunopeptidome. In this review, we discuss published immunopeptidomics studies from recent years, grouped into three main domains: i) basic, ii) pre-clinical and iii) clinical research and applications. We review selected fundamental immunopeptidomics studies on the antigen processing and presentation machinery, on HLA restriction and studies that advanced our understanding of various diseases, and how exploration of the antigenic landscape allowed immune targeting at the pre-clinical stage, paving the way to pioneering exploratory clinical trials where immunopeptidomics is directly implemented in the conception of innovative treatments for cancer patients.
Mots-clé
Humans, Histocompatibility Antigens Class I, Histocompatibility Antigens Class II, HLA Antigens, Antigen Presentation, Peptides, Antigen Discovery, Clinical applications, Immunopeptidomics, Mass spectrometry
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/03/2023 15:22
Dernière modification de la notice
29/03/2023 6:51
Données d'usage